Actively Recruiting
Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial
Led by University of Erlangen-Nürnberg Medical School · Updated on 2017-08-11
50
Participants Needed
1
Research Sites
791 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trial examines the feasibility and toxicity of focal brachytherapy in patients with low-risk prostate cancer.
CONDITIONS
Official Title
Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 18
- Histologically confirmed prostate cancer
- Gleason score of index lesion 6 or less (3+3)
- Tumor stage cT1-2a cN0 cM0
- Unilateral affection with index lesion 0.5 ml or less; no more than 25% of biopsy affected
- PSA level 10 ng/ml or lower
- Prostate volume less than 60 m^3
- No distant metastasis
- Life expectancy greater than 10 years
- Provided informed consent
You will not qualify if you...
- Tumor stage T2b or higher
- Known metastasis including N+ and/or M1
- Inability to undergo general or peridural anesthesia
- Coagulation disorders
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital
Erlangen, Germany, 91054
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here